NCT03449238: Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

NCT03449238
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 19 Years to 90 Years (Adult, Senior)
Location of Metastases: Brain
Additional Notes: Must have at least 2 intracranial untreated metastases
Exclusions: Prior whole brain irradiation
https://ClinicalTrials.gov/show/NCT03449238

Comments are closed.

Up ↑